TARA - Protara begins dosing in early-stage trial of TARA-002 for bladder cancer

Protara Therapeutics (NASDAQ:TARA) said it dosed the first patient in a phase 1 trial of its cell therapy TARA-002 to treat non-muscle invasive bladder cancer (NMIBC). The primary objective of the early-stage trial, dubbed ADVANCED-1, is to evaluate the safety, tolerability and signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for a planned phase 2 trial. The trial will evaluate TARA-002 in patients with NMIBC with high-grade carcinoma in situ and high-grade papillary tumors, who have not received prior treatment and also those people who have previously received therapy. The U.S. FDA had cleared the company’s Investigational New Drug application to begin trial for TARA-002 in October last year.

For further details see:

Protara begins dosing in early-stage trial of TARA-002 for bladder cancer